Missed Topics Study Guide: ANCC/AANP.
1.
Levels of
Prevention
Primary
, Missed Topics Study Guide: ANCC/AANP.
prevention
Secondary
prevention Tertiary
prevention
2. Tertiary Prevention Tertiary prevention is post-diagnosis and is
aimed at reducing morbidity and mortality.
EXAMPLES: Quitting smoking, getting annual
vacci- nations, and staying away from people
who are sick are all ways to prevent COPD
exacerbations, which is tertiary prevention.
3. Secondary Prevention secondary prevention is about early
recognition.
Think SCREENINGS!!!!
4. Primary prevention Primary prevention is aimed at preventing
disease
5. Classifications of COPD exacerbations COPD exacerbations can be classified as
mild, mod-
erate, or severe depending on what was
needed to get the exacerbation under control.
Mild exacerba- tions are treated with a short
acting beta agonist (SABA) like albuterol
(ProAir). Moderate exacerba- tions require a
SABA plus antibiotics and steroids.
Exacerbations that are referred to the hospital
and out of the treatment scope for primary
care are labeled as severe.
6. COPD treatment groups COPD treatment groups are based on the
patient's
,Missed Topics Study Guide: ANCC/AANP.
CAT score (<10 vs 10 or greater) and
exacerba- tions/hospitalizations. This
patient's CAT score is greater than 10 and
they have not stated any COPD
exacerbations and/or any COPD
exacerbations that
, Missed Topics Study Guide: ANCC/AANP.
led to hospitalzation. That would place this
pa- tient in treatment group B, which can be
treated with the long actings - either a long
acting beta agonist (LABA) or long acting
muscarinic antag- onist (LAMA). Albuterol
(Pro-Air) is a short acting beta agonist
(SABA). Fluticasone (Flovent) is an in- haled
corticosteroid. Methylprednisolone (Medrol)
is a steroid (typically given oral or IV).
Salmeterol (Serevent) is a LABA making it an
appropriate treat- ment for group B COPD.
7. Lab for SLE antinuclear antibody test (ANA) as lupus is a
prima- ry ditterential. Although this test does
not confirm a diagnosis of lupus, it can be
highly indicative
of this diagnosis in the presence of other
criteria. The criteria from the American College
of Rheuma- tology includes: malar rash, a
discoid rash, pho- tosensitivity, oral/nasal
ulcers, nonerosive arthritis, cardio-pulmonary
issues, renal issues, neurological concerns,
immunological disorders, a positive an-
tinuclear antibody test, and hematologic
disorders. A person must have 4 out of the
11 criteria to be diagnosed with lupus. An
ESR or CRP would not be helpful in this
case, as the patient is not report- ing any
symptoms associated with inflammation or
infection. While fatigue and brain fog can be
associated with thyroid dysfunction, this would
not explain the patient's new onset rash or
1.
Levels of
Prevention
Primary
, Missed Topics Study Guide: ANCC/AANP.
prevention
Secondary
prevention Tertiary
prevention
2. Tertiary Prevention Tertiary prevention is post-diagnosis and is
aimed at reducing morbidity and mortality.
EXAMPLES: Quitting smoking, getting annual
vacci- nations, and staying away from people
who are sick are all ways to prevent COPD
exacerbations, which is tertiary prevention.
3. Secondary Prevention secondary prevention is about early
recognition.
Think SCREENINGS!!!!
4. Primary prevention Primary prevention is aimed at preventing
disease
5. Classifications of COPD exacerbations COPD exacerbations can be classified as
mild, mod-
erate, or severe depending on what was
needed to get the exacerbation under control.
Mild exacerba- tions are treated with a short
acting beta agonist (SABA) like albuterol
(ProAir). Moderate exacerba- tions require a
SABA plus antibiotics and steroids.
Exacerbations that are referred to the hospital
and out of the treatment scope for primary
care are labeled as severe.
6. COPD treatment groups COPD treatment groups are based on the
patient's
,Missed Topics Study Guide: ANCC/AANP.
CAT score (<10 vs 10 or greater) and
exacerba- tions/hospitalizations. This
patient's CAT score is greater than 10 and
they have not stated any COPD
exacerbations and/or any COPD
exacerbations that
, Missed Topics Study Guide: ANCC/AANP.
led to hospitalzation. That would place this
pa- tient in treatment group B, which can be
treated with the long actings - either a long
acting beta agonist (LABA) or long acting
muscarinic antag- onist (LAMA). Albuterol
(Pro-Air) is a short acting beta agonist
(SABA). Fluticasone (Flovent) is an in- haled
corticosteroid. Methylprednisolone (Medrol)
is a steroid (typically given oral or IV).
Salmeterol (Serevent) is a LABA making it an
appropriate treat- ment for group B COPD.
7. Lab for SLE antinuclear antibody test (ANA) as lupus is a
prima- ry ditterential. Although this test does
not confirm a diagnosis of lupus, it can be
highly indicative
of this diagnosis in the presence of other
criteria. The criteria from the American College
of Rheuma- tology includes: malar rash, a
discoid rash, pho- tosensitivity, oral/nasal
ulcers, nonerosive arthritis, cardio-pulmonary
issues, renal issues, neurological concerns,
immunological disorders, a positive an-
tinuclear antibody test, and hematologic
disorders. A person must have 4 out of the
11 criteria to be diagnosed with lupus. An
ESR or CRP would not be helpful in this
case, as the patient is not report- ing any
symptoms associated with inflammation or
infection. While fatigue and brain fog can be
associated with thyroid dysfunction, this would
not explain the patient's new onset rash or
